Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRUDHESA vs AKBETA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRUDHESA is a fixed-dose combination of sumatriptan (a serotonin 5-HT1B/1D receptor agonist) and naproxen sodium (a nonsteroidal anti-inflammatory drug). Sumatriptan causes vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, while naproxen inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis.
AKBETA is not a recognized drug; please verify the drug name.
Acute treatment of migraine with or without aura in adults
No verified indications
10 mg intranasally once, may repeat after 2 hours if needed; maximum 20 mg per 24 hours.
Metoprolol tartrate: 50-100 mg orally twice daily; metoprolol succinate: 25-200 mg orally once daily.
Terminal elimination half-life is approximately 2.4 hours (range 1.7-3.6 hours) following intravenous administration. Clinical context: Due to rapid clearance, repeated dosing is recommended for acute migraine attacks.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 10-20 hours in severe renal impairment.
Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9 (major) and CYP1A2 (minor).
Unknown
Trudhesa (dihydroergotamine mesylate) is primarily eliminated via hepatic metabolism, with approximately 10% excreted unchanged in urine and 90% as metabolites in bile/feces.
Renal excretion accounts for 80-85% of the dose, primarily as unchanged drug; biliary/fecal elimination is 10-15%.
Approximately 90-93% bound to plasma proteins, primarily to albumin.
60-70% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution (Vd) is approximately 14 L/kg (range 10-20 L/kg), indicating extensive tissue distribution, including binding to serotonin receptors in the CNS.
Vd is 1.0-2.0 L/kg, indicating extensive tissue distribution.
Intranasal administration: Absolute bioavailability approximately 15-20% (range 10-30%), due to extensive first-pass hepatic metabolism.
Oral: 50-60% due to first-pass hepatic metabolism; IV: 100%.
No dosage adjustment required for mild to moderate renal impairment; no data for severe impairment (e GFR <30 m L/min/1.73 m2).
No dose adjustment required for mild to moderate renal impairment; in severe renal impairment (GFR < 10 m L/min), administer with caution.
Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in moderate impairment (Child-Pugh class B) with no specific dose adjustment defined.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not approved for use in pediatric patients; safety and efficacy not established.
1-2 mg/kg per day orally in divided doses; maximum 200 mg/day.
No specific dose adjustment recommended, but consider potential increased sensitivity to adverse effects due to comorbidities or concomitant medications.
Initiate at lower end of dosing range (e.g., 25 mg once daily for metoprolol succinate), titrate slowly due to increased risk of bradycardia and hypotension.
Cardiovascular Risk: NSAIDs, including naproxen, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular risk factors or existing cardiovascular disease are at greater risk.
No boxed warning applicable
Cardiovascular and cerebrovascular effects; risk of myocardial infarction, stroke, and hypertension; gastrointestinal bleeding (NSAID-related); serotonin syndrome with concomitant serotonergic drugs; renal effects; anaphylactic reactions; exacerbation of asthma; sulfonamide allergy (cross-reactivity).
No warnings due to lack of data
History of ischemic heart disease, coronary artery disease, or cerebrovascular disease; peripheral vascular disease; uncontrolled hypertension; hemiplegic or basilar migraine; recent use (within 24 hours) of another 5-HT1 agonist or ergotamine; concurrent MAO-A inhibitor use; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; severe hepatic impairment; third trimester of pregnancy.
No contraindications identified
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4 and may increase ergotamine toxicity. No other significant food interactions reported.
No significant food interactions. Taking with meals may reduce gastrointestinal irritation. Avoid excessive salt intake as it may exacerbate Meniere's symptoms.
Trimester 1: Increased risk of congenital abnormalities, particularly neural tube defects, due to topiramate exposure. Trimester 3: Risk of transient neonatal hyperbilirubinemia and sulfonamide-related adverse effects.
Pregnancy category D. First trimester: Associated with fetal bradycardia, hypoglycemia, and growth restriction; beta-blocker exposure increases risk of low birth weight. Second trimester: Continued risk of fetal bradycardia and growth restriction; may cause placental hypoperfusion. Third trimester: Risk of neonatal hypoglycemia, bradycardia, and respiratory depression; beta-blockade may attenuate fetal heart rate response to distress.
Topiramate is excreted into breast milk; M/P ratio 0.86. Infant exposure estimated at 10-20% of maternal weight-adjusted dose. Monitor for diarrhea, drowsiness, and poor feeding.
Atenolol is excreted in breast milk with a high M/P ratio of approximately 4.6. Peak milk levels occur 2-4 hours after dose. Due to potential for infant bradycardia and hypoglycemia, use is not recommended; if used, monitor infant for signs of beta-blockade.
May require dose increase due to decreased plasma concentrations in pregnancy. Monitor topiramate levels and adjust dose to maintain therapeutic effect. Consider baseline and periodic monitoring.
Atenolol is not recommended in pregnancy due to fetotoxicity; use alternative beta-blocker with better safety profile (e.g., labetalol). If used, dose requirements may increase due to expanded plasma volume and increased renal clearance; dose should be individualized based on maternal heart rate and blood pressure response.
TRUDHESA (dihydroergotamine mesylate) is an intranasal formulation for acute migraine. Administer one spray (0.5 mg) in each nostril, repeated after 15 minutes if needed (total 2 mg). Avoid in basilar or hemiplegic migraine due to vasospasm risk. Max dose: 3 mg/day, 4 mg/week. Contraindicated with CYP3A4 inhibitors (e.g., macrolides, azoles, protease inhibitors) due to ergotism risk. Monitor for signs of ischemia.
AKBETA (betahistine) is primarily used for Meniere's disease. Titrate dose gradually to minimize GI upset. Avoid in patients with pheochromocytoma or severe asthma. Monitor for hypotension and bradycardia. Efficacy may take weeks to manifest.
Use at the first sign of migraine; not for prevention.,Prime the pump 4 times before first use or if not used for 7+ days.,Do not exceed 2 sprays per nostril per attack or 8 sprays total per week.,Avoid within 24 hours of other triptans or ergotamines.,Seek medical help if symptoms of chest tightness, severe abdominal pain, or numbness occur.
Take with or after meals to reduce stomach upset.,Do not drive or operate machinery if you experience dizziness or drowsiness.,Report any worsening of asthma symptoms or irregular heartbeat.,Avoid alcohol as it may increase side effects like dizziness.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRUDHESA vs AKBETA, answered by our medical review team.
TRUDHESA is a Antimigraine (Ergot Alkaloid) that works by TRUDHESA is a fixed-dose combination of sumatriptan (a serotonin 5-HT1B/1D receptor agonist) and naproxen sodium (a nonsteroidal anti-inflammatory drug). Sumatriptan causes vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, while naproxen inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis.. AKBETA is a Beta Blocker (Ophthalmic) that works by AKBETA is not a recognized drug; please verify the drug name.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRUDHESA and AKBETA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRUDHESA is: 10 mg intranasally once, may repeat after 2 hours if needed; maximum 20 mg per 24 hours.. The standard adult dose of AKBETA is: Metoprolol tartrate: 50-100 mg orally twice daily; metoprolol succinate: 25-200 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRUDHESA and AKBETA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRUDHESA is classified as Category C. Trimester 1: Increased risk of congenital abnormalities, particularly neural tube defects, due to topiramate exposure. Trimester 3: Risk of transient neonatal hyperbilirubinemia an. AKBETA is classified as Category C. Pregnancy category D. First trimester: Associated with fetal bradycardia, hypoglycemia, and growth restriction; beta-blocker exposure increases risk of low birth weight. Second tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.